hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
Category: #health  By Pankaj Singh  Date: 2019-08-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has reportedly announced that AGS-v PLUS, an investigational vaccine created to protect against several different mosquito-borne diseases, will be examined in a phase 1 clinical trial. The phase 1 trial will be conducted by the NIH at the University of Maryland School of Medicine. AGS-v PLUS vaccine was developed by Imutex Limited which is 49 percent joint venture of hVIVO with the SEEK Group. The study has received additional funding from the UK Department of Health and Social Care which is managed by Innovate UK.

Apparently, AGS-v PLUS has been created to activate an immune reaction to the proteins in mosquito saliva, which can hold many diverse pathogens, such as Malaria and Zika. This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects. The vaccine may also contain a mosquito control element. The study will gather data on the mosquitoes’ fertility which feed on vaccinated volunteers.

Seemingly, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has earlier tested a previous version of AGS-v vaccine in a first-in-human trial. The trial was organized in NIAID’s Laboratory of Infectious Diseases’ Special Clinical Studies Unit at the NIH Clinical Center in Bethesda, Maryland. The final outcomes of this trial are expected in due course.

Trevor Phillips, Executive Chairman, hVIVO, has reportedly stated that the company is pleased to see the association with NIH and the University of Maryland School of Medicine remains as AGS-v PLUS, one of the assets in the joint venture Imutex, transfers into the clinic. The company is delighted that the asset development has been ongoing with NIAID-funded researchers analyzing the vaccine and extra funding for the trial by Innovate UK, he further added.

 

Source credit: https://imutex.com/wp-content/uploads/2019/07/AGS-v_PLUS_Phase_1_FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

TikTok to donate 4 Lakh safety suits to Indian healthcare workers
TikTok to donate 4 Lakh safety suits to Indian healthcare workers
By Pankaj Singh

Amidst lowering availability of medical equipment and safety gear in India during the current COVID-19 crisis, Chinese video-sharing company, TikTok has made a generous gesture by announcing that it will donate ab...

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...